The effects of interleukin-1β in modulating osteoclast-conditioned medium’s influence on gelatinases in chondrocytes through mitogen-activated protein kinases

Abstract

Signaling molecules released by bone-resorbing cells (osteoclasts) can regulate the activity of the gelatinase enzyme in cartilage. Xiao-Xiao Cai and co-workers at Sichuan University in China explored the hypothesis that cartilage metabolism might be controlled by signals from bone cells. They found that the protein interleukin-1β (IL-1β) in the fluid around osteoclasts increased the activity of gelatinase in mouse cartilage cells in tissue culture. Changes in gelatinase activity have previously been implicated in diseases that involve disruption of cartilage metabolism, including osteoarthritis. The researchers also found that IL-1βs effect on gelatinase activity was mediated through pathways involving regulatory proteins known as mitogen-activated protein kinases. These insights will help in understanding the role of gelatinase in the maintenance of cartilage in both health and disease.

Keywords

chondrocyte / gelatinases / interleukin-1β / matrix crosstalk / osteoarthritis / osteoclast

References

[1] Wieland HA, Michaelis M, Kirschbaum BJ. Osteoarthritis – an untreatable disease. Nat Rev Drug Discov, 2005, 4(4): 331-344.

[2] Funck-Brentano T, Cohen-Solal M. Crosstalk between cartilage and bone: when bone cytokines matter. Cytokine Growth Factor Rev, 2011, 22(2): 91-97.

[3] Haywood L, McWilliams DF, Pearson CI. Inflammation and angiogenesis in osteoarthritis. Arthritis Rheum, 2003, 48(8): 2173-2177.

[4] D’andrea P, Calabrese A, Grandolfo M. Intercellular calcium signalling between chondrocytes and synovial cells in co-culture. Biochem J, 1998, 329(Pt 3): 681-687.

[5] Dingle JT, Saklatvala J, Hembry R. A cartilage catabolic factor from synovium. Biochem J, 1979, 184(1): 177-180.

[6] Dreier R, Wallace S, Fuchs S. Paracrine interactions of chondrocytes and macrophages in cartilage degradation: articular chondrocytes provide factors that activate macrophage-derived pro-gelatinase B (pro-MMP-9). J Cell Sci, 2001, 114(Pt 21): 3813-3822.

[7] Sandy JD. A contentious issue finds some clarity: on the independent and complementary roles of aggrecanase activity and MMP activity in human joint aggrecanolysis. Osteoarthr Cartil, 2006, 14(2): 95-100.

[8] Page-McCaw A, Ewald AJ, Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol, 2007, 8(3): 221-233.

[9] Elliott SF, Coon CI, Hays E. Bcl-3 is an interleukin-1-responsive gene in chondrocytes and synovial fibroblasts that activates transcription of the matrix metalloproteinase 1 gene. Arthritis Rheum, 2002, 46(12): 3230-3239.

[10] Takaishi H, Kimura T, Dalal S. Joint diseases and matrix metalloproteinases: a role for MMP-13. Curr Pharm Biotechnol, 2008, 9(1): 47-54.

[11] Grottkau BE, Lin Y. Osteogenesis of adipose-derived stem cells. Bone Res, 2013, 1(2): 133-145.

[12] Sang QA, Bodden MK, Windsor LJ. Activation of human progelatinase A by collagenase and matrilysin: activation of procollagenase by matrilysin. J Protein Chem, 1996, 15(3): 243-253.

[13] Geng Y, Valbracht J, Lotz M. Selective activation of the mitogen-activated protein kinase subgroups c-Jun NH2 terminal kinase and p38 by IL-1 and TNF in human articular chondrocytes. J Clin Invest, 1996, 98(10): 2425-2430.

[14] Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science, 2002, 298(5600): 1911-1912.

[15] Raymond L, Eck S, Mollmark J. Interleukin-1 beta induction of matrix metalloproteinase-1 transcription in chondrocytes requires ERK-dependent activation of CCAAT enhancer-binding protein-beta. J Cell Physiol, 2006, 207(3): 683-688.

[16] Mengshol JA, Vincenti MP, Coon CI. Interleukin-1 induction of collagenase 3 (matrix metalloproteinase 13) gene expression in chondrocytes requires p38, c-Jun N-terminal kinase, and nuclear factor kappaB: differential regulation of collagenase 1 and collagenase 3. Arthritis Rheum, 2000, 43(4): 801-811.

[17] Fruebis J, Tsao TS, Javorschi S. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci U S A, 2001, 98(4): 2005-2010.

[18] Long DL, Loeser RF. p38gamma mitogen-activated protein kinase suppresses chondrocyte production of MMP-13 in response to catabolic stimulation. Osteoarthr Cartil, 2010, 18(9): 1203-1210.

[19] Alge-Priglinger CS, Kreutzer T, Obholzer K. Oxidative stress-mediated induction of MMP-1 and MMP-3 in human RPE cells. Invest Ophthalmol Vis Sci, 2009, 50(11): 5495-5503.

[20] Nakai K, Kawato T, Morita T. Angiotensin II induces the production of MMP-3 and MMP-13 through the MAPK signaling pathways via the AT₁ receptor in osteoblasts. Biochimie, 2013, 95(4): 922-933.

[21] Vu TH, Shipley JM, Bergers G. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell, 1998, 93(3): 411-422.

[22] Crane JL, Zhao L, Frye JS. IGF-1 signaling is essential for differentiation of mesenchymal stem cells for peak bone mass. Bone Res, 2013, 1(2): 186-194.

[23] Kadri A, Funck-Brentano T, Lin H. Inhibition of bone resorption blunts osteoarthritis in mice with high bone remodelling. Ann Rheum Dis, 2010, 69(8): 1533-1538.

[24] Xie J, Wang C, Huang DY. TGF-beta1 induces the different expressions of lysyl oxidases and matrix metalloproteinases in anterior cruciate ligament and medial collateral ligament fibroblasts after mechanical injury. J Biomech, 2013, 46(5): 890-898.

[25] Pickarski M, Hayami T, Zhuo Y. Molecular changes in articular cartilage and subchondral bone in the rat anterior cruciate ligament transection and meniscectomized models of osteoarthritis. BMC Musculoskelet Disord, 2011, 12: 197.

[26] Aigner T, Zien A, Gehrsitz A. Anabolic and catabolic gene expression pattern analysis in normal versus osteoarthritic cartilage using complementary DNA-array technology. Arthritis Rheum, 2001, 44(12): 2777-2789.

[27] Daouti S, Latario B, Nagulapalli S. Development of comprehensive functional genomic screens to identify novel mediators of osteoarthritis. Osteoarthr Cartil, 2005, 13(6): 508-518.

[28] Lee JH, Fitzgerald JB, DiMicco MA. Co-culture of mechanically injured cartilage with joint capsule tissue alters chondrocyte expression patterns and increases ADAMTS5 production. Arch Biochem Biophys, 2009, 489(1/2): 118-126.

[29] Radin EL, Rose RM . Role of subchondral bone in the initiation and progression of cartilage damage. Clin Orthop Relat Res 1986; (213): 34–40.

[30] Radin EL, Paul IL, Tolkoff MJ. Subchondral bone changes in patients with early degenerative joint disease. Arthritis Rheum, 1970, 13(4): 400-405.

[31] Grottkau BE, Purudappa PP, Lin YF. Multilineage differentiation of dental pulp stem cells from green fluorescent protein transgenic mice. Int J Oral Sci, 2010, 2(1): 21-27.

[32] Mitchell PG, Magna HA, Reeves LM. Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage. J Clin Invest, 1996, 97(3): 761-768.

[33] El Mabrouk M, Sylvester J, Zafarullah M. Signaling pathways implicated in oncostatin M-induced aggrecanase-1 and matrix metalloproteinase-13 expression in human articular chondrocytes. Biochim Biophys Acta, 2007, 1773(3): 309-320.

[34] Itthiarbha A, Phitak T, Sanyacharernkul S. Polyoxypregnane glycoside from Dregea volubilis extract inhibits IL-1β-induced expression of matrix metalloproteinase via activation of NF-κB in human chondrocytes. In Vitro Cell Dev Biol Anim, 2012, 48(1): 43-53.

[35] Rizvi NA, Humphrey JS, Ness EA. A phase I study of oral BMS-275291, a novel nonhydroxamate sheddase-sparing matrix metalloproteinase inhibitor, in patients with advanced or metastatic cancer. Clin Cancer Res, 2004, 10(6): 1963-1970.

[36] Kimura H, Yukitake H, Suzuki H. The chondroprotective agent ITZ-1 inhibits interleukin-1 beta-induced matrix metalloproteinase-13 production and suppresses nitric oxide-induced chondrocyte death. J Pharmacol Sci, 2009, 110(2): 201-211.

[37] Prasadam I, Farnaghi S, Feng JQ. Impact of extracellular matrix derived from osteoarthritis subchondral bone osteoblasts on osteocytes: role of integrin β1 and focal adhesion kinase signaling cues. Arthritis Res Ther, 2013, 15(5): R150.

[38] Corry DB, Rishi K, Kanellis J. Decreased allergic lung inflammatory cell egression and increased susceptibility to asphyxiation in MMP2-deficiency. Nat Immunol, 2002, 3(4): 347-353.

[39] Esparza J, Kruse M, Lee J. MMP-2 null mice exhibit an early onset and severe experimental autoimmune encephalomyelitis due to an increase in MMP-9 expression and activity. FASEB J, 2004, 18(14): 1682-1691.

[40] Zhang D, Bar-Eli M, Meloche S. Dual regulation of MMP-2 expression by the type 1 insulin-like growth factor receptor: the phosphatidylinositol 3-kinase/Akt and Raf/ERK pathways transmit opposing signals. J Biol Chem, 2004, 279(19): 19683-19690.

[41] Al-Hizab F, Clegg PD, Thompson CC. Microscopic localization of active gelatinases in equine osteochondritis dissecans (OCD) cartilage. Osteoarthr Cartil, 2002, 10(8): 653-661.

[42] Li P, Hu M, Sun S. Fluid flow-induced calcium response in early or late differentiated osteoclasts. Ann Biomed Eng, 2012, 40(9): 1874-1883.